Genetic alterations of drug tolerance

Trask B et al. (1993) Fluorescence in situ hybridization mapping of human chromosome 19: cytogenetic band location of 540 cosmids and 70 genes or DNA markers.

Paolini M et al. (1999) Co-carcinogenic effect of beta-carotene.

Thum T et al. (2000) Gene expression in distinct regions of the heart.

Nebert DW et al. (1987) P450 genes: structure, evolution, and regulation.

Yamano S et al. (1990) The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes.

Wood AW et al. (1974) Genetic variation in coumarin hydroxylase activity in the mouse (Mus musculus).

Lush IE et al. (1978) Genetic variation between mice in their metabolism of coumarin and its derivatives.

London SJ et al. (1999) Genetic variation of CYP2A6, smoking, and risk of cancer.

Oscarson M et al. (1999) Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population.

Miyamoto M et al. (1999) CYP2A6 gene deletion reduces susceptibility to lung cancer.

Gu DF et al. (2000) The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit.

Hoffman SM et al. (2001) Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19.

Daigo S et al. (2002) A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.

Oscarson M et al. (2002) Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity.

Saito S et al. (2003) Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population.

OMURA T et al. (1964) THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Gambier N et al. (2005) Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort.

Palmer G et al. (1991) Nomenclature Committee of the International Union of Biochemistry (NC-IUB). Nomenclature of electron-transfer proteins. Recommendations 1989.

None (1991) Proposed role of drug-metabolizing enzymes: regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions.

Mwenifumbo JC et al. (2008) Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent.

Miles JS et al. (1990) Close linkage of the cytochrome P450IIA gene subfamily (Cyp2a) to Cyp2b and Coh on mouse chromosome 7.

None (1979) Multiple forms of inducible drug-metabolizing enzymes: a reasonable mechanism by which any organism can cope with adversity.

Matsunaga T et al. (1990) Structure and in vitro transcription of the rat CYP2A1 and CYP2A2 genes and regional localization of the CYP2A gene subfamily on mouse chromosome 7.

Miles JS et al. (1989) Close linkage of the human cytochrome P450IIA and P450IIB gene subfamilies: implications for the assignment of substrate specificity.

Yamano S et al. (1989) cDNA and deduced amino acid sequences of human P450 IIA3 (CYP2A3).

Negishi M et al. (1989) Mouse steroid 15 alpha-hydroxylase gene family: identification of type II P-450(15)alpha as coumarin 7-hydroxylase.

Phillips IR et al. (1985) A cytochrome P-450 gene family mapped to human chromosome 19.

Davis MB et al. (1986) Regional localization of a human cytochrome P-450 (CYP1) to chromosome 19q13.1-13.3.

None (1987) Linkage between the loci for peptidase D and cytochrome P-450 (CYP1) on chromosome 19.

Phillips IR et al. (1985) Isolation and sequence of a human cytochrome P-450 cDNA clone.

Wainwright BJ et al. (1985) RFLP for a human cytochrome P-450 gene at 19q13.1-qter (HGM8 provisional designation CYPI).

Fernandez-Salguero P et al. (1995) A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles.

Nelson DR et al. () The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature.

Aida K et al. (1994) Lack of the steroid 15 alpha-hydroxylase gene (Cyp2a-4) in wild mouse strain Mus spretus: rapid evolution of the P450 gene superfamily.

Nakajima M et al. (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine.

Hadidi H et al. (1997) A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin.

Yokoi T et al. (1998) Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

None (1976) Coumarin-7-hydroxylase activity in microsomes from needle biopsies of normal and diseased human liver.

Pianezza ML et al. (1998) Nicotine metabolism defect reduces smoking.

Oscarson M et al. (1998) Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase.

Kleinbloesem CH et al. (1984) Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man.

Liou YH et al. (2006) The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.

Nebert DW et al. (1987) The P450 gene superfamily: recommended nomenclature.

Gray IC et al. (1995) A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24.

Daly AK et al. (1996) Nomenclature for human CYP2D6 alleles.

Idle JR et al. (2000) Medical implications of HGP's sequence of chromosome 22.

Nakamura K et al. (2002) CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.

Nelson DR et al. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.

Gasche Y et al. (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism.

Gaedigk A et al. (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.

Koren G et al. (2006) Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother.

Desmeules J et al. (1991) Impact of environmental and genetic factors on codeine analgesia.

Gough AC et al. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus.

Hanioka N et al. (1990) The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site.

Kagimoto M et al. (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.

Chen X et al. (1995) The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease.

Johansson I et al. (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

Panserat S et al. (1994) DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers.

Saxena R et al. (1994) Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.

Broly F et al. (1995) A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency.

Steen VM et al. (1995) Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene.

Marez D et al. (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.

Yue QY et al. (1997) Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators.

Guengerich FP et al. (1986) Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation.

Gough SM et al. (2003) Refined physical map of the human PAX2/HOX11/NFKB2 cancer gene region at 10q24 and relocalization of the HPV6AI1 viral integration site to 14q13.3-q21.1.

Tate SK et al. (2005) Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

Kohn MH et al. (2000) A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans.

et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data.

Aithal GP et al. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Kidd RS et al. (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

Aithal GP et al. (2000) Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.

Xie HG et al. (2001) Molecular basis of ethnic differences in drug disposition and response.

Leung AY et al. (2001) Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.

Higashi MK et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Williams PA et al. (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin.

Kirchheiner J et al. (2003) Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.

Fichtlscherer S et al. (2004) Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.

King BP et al. (2004) Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.

Sanderson S et al. (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.

Li T et al. (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation.

Steward DJ et al. (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

Caldwell MD et al. (2008) CYP4F2 genetic variant alters required warfarin dose.

Yuan HY et al. (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

Lessard E et al. (1997) Role of CYP2D6 in the N-hydroxylation of procainamide.

Lessard E et al. (1999) Involvement of CYP2D6 activity in the N-oxidation of procainamide in man.

Lindberg RL et al. (1992) Molecular characterization of the murine Coh locus: an amino acid difference at position 117 confers high and low coumarin 7-hydroxylase activity in P450coh.

O'REILLY RA et al. (1964) HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED.

Shikata E et al. (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity.

Rost S et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Takahashi H et al. (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Cooper GM et al. (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

Limdi NA et al. (2008) VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.

Borgiani P et al. (2009) CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.

Takeuchi F et al. (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

Nebert DW et al. () The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature.

Alving BM et al. (1985) Hereditary warfarin resistance. Investigation of a rare phenomenon.

Vesell ES et al. (1968) Genetic control of dicumarol levels in man.

None (1970) The second reported kindred with hereditary resistance to oral anticoagulant drugs.

Pool JG et al. (1968) Warfarin resistance in the rat.

Lewis RJ et al. (1967) Warfarin resistance.

Greavses JH et al. (1967) Heritable resistance to warfarin in rats.

Whitlon DS et al. (1978) Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition.

Tucker GT et al. (1977) Polymorphic hydroxylation of debrisoquine.

Heim MH et al. (1992) Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6.

Heim M et al. (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Kimura S et al. (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.

Matsunaga E et al. (1989) The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats.

Skoda RC et al. (1988) Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.

Gonzalez FJ et al. (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Gonzalez FJ et al. (1988) Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

Eichelbaum M et al. (1987) Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

Gonzalez FJ et al. (1987) Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism.

Harmer D et al. (1986) The relationship between the acetylator and the sparteine hydroxylation polymorphisms.

Eichelbaum M et al. (1986) The genetic polymorphism of sparteine metabolism.

Eichelbaum M et al. (1985) Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.

Distlerath LM et al. (1984) Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.

Dahl ML et al. (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.

Agúndez JA et al. (1995) Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population.

Mura C et al. (1993) DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.

Johansson I et al. (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

Bertilsson L et al. (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.

Gough AC et al. (1993) Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis.

Nelson DR et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

None (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?

Sachse C et al. (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

McLellan RA et al. (1997) Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians.

Tyndale RF et al. (1997) Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence.

Mikus G et al. (1998) Relevance of deficient CYP2D6 in opiate dependence.

Lundqvist E et al. (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes.

Bathum L et al. (1998) Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.

Tateishi T et al. (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population.

Brown MA et al. (2000) Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis.

Payami H et al. (2001) Parkinson's disease, CYP2D6 polymorphism, and age.

Elbaz A et al. (2004) CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease.

Deng Y et al. (2004) Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease.

Pilotto A et al. (2009) Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease.

Schroth W et al. (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

Sullivan-Klose TH et al. (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

None (2001) Racial differences in the response to drugs--pointers to genetic differences.

Maekawa K et al. (2006) Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese.

Speed WC et al. (2009) Global variation in CYP2C8-CYP2C9 functional haplotypes.

Ross KA et al. (2010) Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.

Shurin SB et al. (2008) Pharmacogenomics--ready for prime time?